BevCanna Enterprises

REVIVE THERAPEUTICS OTCMKTSRVVTF STOCK QUOTE

http://revivethera.com/

LATEST NEWS FROM REVIVE THERAPEUTICS

Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics

Revive To Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India

Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip

Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19

Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™

Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional Patent Application

Revive Reschedules Annual and Special Meeting and Provides Dial-In Information

Revive Adjourns Annual and Special Meeting

CEO Presenting on the Emerging Growth Conference on April 14; Register now

Revive Provides Dial-In Information for Annual and Special Meeting

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application

UPDATE -- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request

PharmaTher Announces Sale of Psilocybin Program

Revive Therapeutics Acquires Unique Psilocybin Assets

Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program

Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering

Revive Therapeutics Files Business Acquisition Report

Revive Therapeutics Included in First Psychedelic Exchange Traded Fund